Brandes Investment Partners LP Buys 90,387 Shares of Kenvue Inc. (NYSE:KVUE)

Brandes Investment Partners LP grew its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,940,712 shares of the company's stock after acquiring an additional 90,387 shares during the period. Brandes Investment Partners LP owned about 0.15% of Kenvue worth $62,784,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Grove Bank & Trust lifted its holdings in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the fourth quarter worth about $29,000. SRS Capital Advisors Inc. lifted its holdings in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after buying an additional 571 shares during the period. Fortitude Family Office LLC lifted its holdings in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock worth $32,000 after buying an additional 777 shares during the period. Finally, Versant Capital Management Inc lifted its holdings in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after buying an additional 1,441 shares during the period. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Up 0.6 %

Shares of KVUE traded up $0.15 on Wednesday, hitting $23.49. 9,646,894 shares of the stock traded hands, compared to its average volume of 16,084,529. The company has a market capitalization of $44.89 billion, a PE ratio of 44.31, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business has a 50 day simple moving average of $21.94 and a 200 day simple moving average of $22.41. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46.

Remove Ads

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the subject of several research analyst reports. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. Barclays decreased their target price on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research note on Friday, January 17th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and decreased their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler raised their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Finally, Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.